In May 2019, the third European Respiratory Society research seminar of the Thoracic Oncology Assembly entitled “New biomarkers, molecules and therapeutic sequences for non-small cell lung carcinoma (NSCLC) in the era of precision medicine” was held in Paris, France. The previous two seminars of the Thoracic Oncology Assembly were on targeted therapy (2015) [1] and immune checkpoint inhibitors (ICI, 2017) [2]. During this seminar, breakout sessions on difficult situations were organised. One of the most original and useful was on the current challenges in brain metastases (BM) management, that we propose to share with European Respiratory Journal readers. Brain metastases remain a major problem in NSCLC. Major improvements in systemic therapies have been observed during the past decade but their impact on brain metastases control as well as their combination with radiation techniques needs further research. http://bit.ly/2Jn4v5a

中文翻译：

---

非小细胞肺癌脑转移治疗的当前挑战

2019年5月，欧洲呼吸学会第三届胸部肿瘤学大会主题为“精准医学时代非小细胞肺癌（NSCLC）的新生物标志物、分子和治疗序列”研究研讨会在法国巴黎举行。胸腔肿瘤学大会的前两次研讨会是关于靶向治疗（2015）[1]和免疫检查点抑制剂（ICI，2017）[2]。在本次研讨会期间，组织了针对困难情况的分组会议。最原始和最有用的内容之一是关于当前脑转移 (BM) 管理的挑战，我们建议与欧洲呼吸杂志的读者分享。脑转移仍然是非小细胞肺癌的主要问题。在过去十年中已经观察到全身疗法的重大改进，但它们对脑转移控制的影响以及它们与放射技术的结合需要进一步研究。http://bit.ly/2Jn4v5a